Actively Recruiting
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.
Led by Centre Hospitalier Régional d'Orléans · Updated on 2025-12-30
180
Participants Needed
1
Research Sites
1043 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Little is known about autophagy during HIV infection. Recently, two different teams reported important dysfunctions of autophagy in HIV-infected patients despite sustained suppressive antiretroviral therapy. As altered autophagy is strongly linked to cellular senescence and chronic inflammation, two hallmarks of HIV-infected patients despite long-term suppressive antiretroviral therapy, it is important to improve our knowledge in the area. Our main objective is to determine whether all or part of mononuclear cell subpopulations (CD4+ and CD8+ T lymphocytes, and monocytes) exhibit a defect in autophagy function in a cohort of HIV-infected patients who are virologically-controlled (plasma HIV RNA \<50 copies / ml) either spontaneously (i.e. HIV controllers or post-treatment controllers) or after they started antiretroviral therapy at different time points (i.e. at the acute or chronic phases), as compared with a control group (i.e. uninfected healthy blood donors).
CONDITIONS
Official Title
Study of Autophagy and the Effects of GALIG Gene Products in HIV-1 Infected Patients Who Are Under Antiretroviral Therapy Since Primary-infection, Chronic Phase, or Never Treated.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Male or female
- Diagnosed with HIV-1 infection (not HIV-2)
- Followed at Orleans' Regional Hospital
- Belongs to one of the defined patient groups/cohorts
- Provided written consent
- Cohort A: on suppressive antiretroviral therapy for at least 4 years started during chronic phase, with CD4 count either below 500 (group A1) or above 500 cells/ml (group A2)
- Cohort B: on suppressive antiretroviral therapy for at least 4 years started within 4 months of acute infection (primary infection)
- Cohort C: untreated with detectable HIV RNA but indicated to start therapy, diagnosed during primary infection (group C1), or chronic phase with CD4 count above 200 (group C2) or below 200 cells/ml (group C3)
- Cohort D: undetectable HIV RNA without therapy, either spontaneously or after treatment interruption
You will not qualify if you...
- Unable to meet study requirements as judged by investigator
- Pregnant or lactating women
- History of inflammatory bowel disease, cancer, intestinal ischemia, malabsorption, or other gastrointestinal dysfunction affecting results
- Presence of blood clotting abnormalities or unexplained bleeding history
- Use of oral or injectable anticoagulants (curative or preventive)
- Protected adults or minors under French Public Health Code
- Under guardianship or curatorship
- Not covered by French health insurance
- Currently participating in another clinical trial evaluating treatment
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
CHU Orleans
Orléans, France, 45067
Actively Recruiting
Research Team
A
Aurélie DESPUJOLS
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
7
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here